Medical Marijuana, Inc. is pleased to announce that the DEA Federal Registry amendment to create a new code for ‘marijuana extracts,’ in no way affects the Company’s hemp oil, containing naturally occurring cannabinoids, including CBD, or its operations.
In the past, the Ninth Circuit Court of Appeals has conclusively held that hemp products, such as those marketed by the Company, which are derived from the part of the Cannabis plant which is exempt from the Controlled Substances Act, is legal for import from Europe.
In the Ninth Circuit case that served to uphold the legality of the Company’s products, the Court struck rules that had been promulgated by the DEA that would have made the Company’s products a scheduled substance and the Court permanently enjoined the DEA from enforcing the stricken rules.
There has been no superseding ruling since the Ninth Circuit’s decision. Therefore, the Company’s products continue to be legal and are not controlled substances. Accordingly, the legality of Medical Marijuana, Inc.’s products remains unchanged in light of this new Federal Registry.
Further, our Company considers the development a major market opportunity, as we have analyzed and followed the chain of custody of our products from inception to ensure that they are derived from the exempt part of the Cannabis plant and are therefore not controlled substances.
One of the many new programs Kannaway shared at the Genesis 2016 event this year was the launch of the Stock Incentive Program. As you may or may not know, Kannaway is owned by publicly traded company, Medical Marijuana Inc., which touts a number of major early accomplishments in the cannabis industry and is one of the largest companies in the Hemp and Cannabidiolspace.
Medical Marijuana Inc. is dubbed a company of firsts for a number of impressive achievements:
- The First Publicly Traded Cannabis Company in the United States
- The First to Establish a Global CBD Pipeline, Making Cannabinoids Available All Over the World
- The First to Deliver Prescription Cannabidiol for Epilepsy, Parkinson’s Disease, Chronic Pain and More.
- The First to License the United States National Institute of Health Patent, “Cannabinoids as Antioxidants and Neuroprotectants.
- And More… (Check out all of Medical Marijuana Inc.’s Firsts…)
Our new stock incentive program is unique in both the cannabis space and the direct sales industry and has our family of brand ambassadors buzzing with excitement.
In order to be eligible, brand ambassadors need to achieve the Ranks of Platinum/Regional Director and above between Nov. 2016 & Nov. 2017. There are multiple tiers of achievement that have larger rewards as Kannaway brand ambassadors work their way up the ranks.
https://kannaway.com/kannaway-launches-new-stock-incentive-program/
We are pleased to announce a new Audio Interview with Stuart Titus, CEO of Medical Marijuana, Inc. Trading Symbol: MJNA – $MJNA Interviewee: Stuart
Source: Stuart Titus – CEO of Medical Marijuana, Inc. $MJNA | The Stock Radio
NEW YORK, Dec. 22, 2015 (GLOBE NEWSWIRE) — Medical Marijuana, Inc. (OTC Pink:MJNA) is proud to announce to shareholders and the public a joint effort with investment portfolio company Kannalife Sciences, Inc. (“Kannalife”) to open an opportunity for the public to “show their green” and participate in a fundraiser for research driven by Kannalife at Temple University for the potential use of cannabidiol as a treatment for chronic traumatic encephalopathy (CTE). CTE is the deadly concussion-related disease plaguing a high percentage of current and retired NFL football players and athletes participating in concussion-related sports.
As part of the fundraising initiative, Medical Marijuana, Inc. and Kannalife have co-sponsored and launched the “Show Your Green” public service announcement (PSA) to create awareness of CTE. Executives from both companies also explained to radio listeners on the U-T Community Spotlight radio show how to make a difference through medical research by visiting http://www.treatCTE.org.
At http://www.treatCTE.org, interested donors can “Show Your Green” by sharing photos along with the PSA video with their social networks. All funds committed will go directly into the CTE research being conducted by Kannalife at Temple University.
What is CTE?
Chronic traumatic encephalopathy is a life-threatening and debilitating disease and each football fan now has the opportunity to support awareness of CTE and make a move toward developing a treatment for the concussive injury. CTE is an oxidative stress (OS) related disease. Neural cells suffer functional or sensory loss in neurodegenerative diseases. Apart from several other environmental or genetic factors, oxidative stress leading to free radical attack on neural cells contributes a calamitous role in neurodegeneration.
Leading the “Show Your Green” PSA at http://www.treatCTE.org is Kannalife’s advisory board member and former NFL star defensive lineman, Marvin Washington. Washington now leads Kannalife’s efforts to expand on raising awareness for the disease and the need for a community-driven effort to support the research and development of therapeutic treatments to fight CTE. Speaking out on CTE and the NFL concussion lawsuit, Washington is calling on the public to “follow the signs” and “follow the science” in interviews including: ESPN’s Outside the Lines, NowThis, MSNBC, and Fox News Sports Court.
From 1988 to 1999, Washington played in 155 games over 11 seasons in the NFL, recording over 40 sacks in his eight years with the New York Jets, two years with the San Francisco 49’ers and as a member of the 1998 Superbowl champion Denver Broncos. Having been diagnosed with three known concussions and a countless number of subconcussions, the former NFL star is extremely passionate about helping individuals who are battling the debilitating and often deadly effects of CTE.
At http://www.treatCTE.org, Washington narrates the first of a short series of “Show Your Green” public awareness campaign videos, as he shares facts about CTE including:
When a football player takes a hit, the impact to the brain is 98 times the force of gravity
A recent study shows that 96% of former NFL players tested positive for CTE
CTE has been linked to dementia, depression and suicide; and
There is currently no effective treatment for CTE
Who is researching CTE?
Kannalife Sciences, Inc. (“Kannalife”), an MJNA portfolio company, is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife currently holds two licenses with the National Institutes of Health for U.S. Patent 6,630,507 “Cannabinoids as Antioxidants and Neuroprotectants.” These licenses are currently in use by Kannalife to develop novel therapeutic drugs to treat chronic traumatic encephalopathy (CTE) and hepatic encephalopathy (HE): http://www.google.com/patents/US6630507. Kannalife’s scientific team has researched the effects of cannabidiol (CBD) on non-differentiated native neuronal cells and has determined cannabidiol’s potential as a target drug candidate to treat oxidative stress-related disorders, CBD’s therapeutic index, and CBD’s limitations in pharmaceutical target drug design.
In tandem with its findings on CBD, Kannalife has developed a new cannabidiol-like molecule called KLS-13019 that, through pre-clinical testing and pharmacokinetic (PK) studies, indicates improvement over CBD’s role as a neuroprotectant through increased potency, as well as potential for greater safety through reduced toxicity. Side-by-side comparisons between CBD and KLS-13019 have also shown that KLS-13019 has marked improvements over CBD in oral bioavailability, CNS penetration, blood-plasma concentrations, and cognitive improvement in murine behavioral models.
How can you help?
You can “Show Your Green” and assist in raising awareness in the fight for a cure for CTE though medical research, by going to http://www.treatCTE.org for details.
NEW YORK, Dec. 10, 2015 (GLOBE NEWSWIRE) — To address the public’s questions about CTE, what the disease is and who it impacts — Medical Marijuana, Inc. (OTC Pink:MJNA) and its portfolio company Kannalife Sciences, Inc. (“Kannalife”) and phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators — are responding with a social media-driven campaign titled “Show Your Green.”
Leading the “Show Your Green” PSA is Kannalife’s advisory board member and former NFL star defensive lineman, Marvin Washington. From 1988 to 1999, Mr. Washington played in 155 games over 11 seasons in the NFL, recording over 40 sacks in his eight years with the New York Jets, two years with the San Francisco 49’ers and as a member of the 1998 Superbowl champion Denver Broncos. Mr. Washington now leads Kannalife’s efforts to expand on raising awareness for the disease and the need for a community driven effort to support the research and development of therapeutic treatments to fight CTE. Having been diagnosed with three known concussions and a countless number of subconcussions, the former NFL star is extremely passionate about helping individuals who are battling the debilitating and often deadly effects of CTE.
In “Show Your Green,” Mr. Washington narrates the first of a short series of “Show Your Green” public awareness campaign videos, as he shares facts about CTE including:
A recent study shows that 96% of former NFL players tested positive for CTE
CTE has been linked to dementia, depression and suicide; and
There is currently no effective treatment for CTE
The “Show Your Green” awareness campaign call-to-action is to post a photo featuring green “eye black” and then sharing the photo within the respondent’s social sphere of influence. By watching “Show Your Green,” every football fan from toddler to titan can have the opportunity to join in and show their green in support of increasing awareness of CTE and the drive towards developing a treatment for concussive injury and CTE, a life threating and debilitating disease. CTE is an oxidative stress (OS) related disease. Neural cells suffer functional or sensory loss in neurodegenerative diseases. Apart from several other environmental or genetic factors, oxidative stress leading to free radical attack on neural cells contributes a calamitous role in neurodegeneration.
Kannalife currently holds two licenses with National Institutes of Health for U.S. Patent 6,630,507 “Cannabinoids as Antioxidants and Neuroprotectants.” These licenses are currently in use by Kannalife to develop novel therapeutic drugs to treat chronic traumatic encephalopathy (CTE) and hepatic encephalopathy (HE): http://www.google.com/patents/US6630507. Kannalife’s scientific team has researched the effects of cannabidiol (CBD) on non-differentiated native neuronal cells and has determined cannabidiol’s potential as a target drug candidate to treat oxidative stress-related disorders, CBD’s therapeutic index, and CBD’s limitations in pharmaceutical target drug design.
“It is a positive step forward to see increased social awareness of traumatic head injury and CTE as well as a call-to-action by the public to creatively drive medical research for a solution,” states Dr. Stuart Titus, Chief Executive Officer of Medical Marijuana, Inc. “A head injury can affect people of all ages – not just NFL players.” Dr. Titus continues, “Kannalife’s efforts are focused on developing a neuroprotective pharmaceutical compound that may have far-reaching implications for furthering the science of neurological medicine. The Company aims to improve quality of life for patients and sufferers of concussions and CTE. The end goal is to end the suffering of patients and their families, who in later stages have been torn apart by the long-term degenerative effects of this terrible condition.”
In tandem with its findings on CBD, Kannalife has developed a new cannabidiol-like molecule called KLS-13019 that, through pre-clinical testing and pharmacokinetic (PK) studies, indicates improvement over CBD’s role as a neuroprotectant through increased potency, as well as potential for greater safety through reduced toxicity. Side-by-side comparisons between CBD and KLS-13019 have also shown that KLS-13019 has marked improvements over CBD in oral bioavailability, CNS penetration, blood-plasma concentrations, and cognitive improvement in murine behavioral models.
You can “Show Your Green” and assist in raising awareness in the fight for a cure for CTE though medical research, by going to http://www.treatCTE.org for details. Campaign spokespersons will be featured Friday, Dec. 11 at 9:00 am – 9:27 am PT on the U-T Community Spotlight Radio Show; the live broadcast can be heard online at http://www.wsradio.com. An archive of the interview can be accessed at http://www.wsradio.com/ut-san-diego/.
SAN DIEGO, Nov. 23, 2015 (GLOBE NEWSWIRE) — Medical Marijuana, Inc. (OTC Pink:MJNA) is pleased to announce the immediate release of its new line of Real Scientific Hemp Oil™ (RSHO™) products with medium-chain triglyceride (MCT) oil for import into Brazil, through its exclusive distributor HempMeds Brasil™. This new liquid product line is an all-natural, non-GMO hemp oil formulation with MCT oil.
“Convenience is key,” states Stuart W. Titus, PhD and Chief Executive Officer of Medical Marijuana, Inc. “After listening to our customers who are using RSHO™ hemp CBD oil, we discovered that many were blending RSHO™ with coconut and/or MCT oil to optimize the consistency when providing it to their children. With the new RSHO™ liquid formulation of MCT oil and convenient dosing spoon, we are simplifying administering the product. We are extremely excited and pleased with this new product line and feel that the popularity of RSHO™ will further expand, as a result of making it more convenient for consumers to use.”
The new RSHO™ liquid is now measured in milliliters. This will allow doctors to prescribe the liquid in a measured dosage they are more familiar with.
MCT oil is found naturally in popular food items, including coconut oil and is a top source of essential healthy fats that are popular with athletes, culinary experts and health and nutrition professionals worldwide, as explained by WebMD.
HempMeds Brasil™ is now making available three new, all-natural hemp oil products with MCT oil:
- Real Scientific Hemp Oil™ [RSHO™] new cannabidiol (CBD) liquid products with MCT oil in Gold.
- Real Scientific Hemp Oil™ [RSHO™] new cannabidiol (CBD) liquid products with MCT oil in Blue.
- Real Scientific Hemp Oil™ new cannabidiol (CBD) in convenient capsules.
Currently on a case-by-case basis, residents of Brazil who have a government-recognized medical indication and want access to RSHO™ hemp oil products, may do so with a doctor’s prescription and formal import approval from ANVISA. The government agency also explains on its website how to apply for an import certificate. HempMeds Brasil™ has been preparing for more than a year, its formal product application and regulatory submission, a process which is expected to be completed by 2016.
In the U.S. hemp is widely regarded as a whole food and super-food. Medical Marijuana, Inc.’s cannabidiol (CBD) hemp oil is derived from the mature stalk of the hemp plant and is considered a food nutrient delivering the benefits of cannabinoids without the psychotropic/euphoric effects of THC. Non-GMO RSHO™ contains no pesticides, herbicides or heavy metals. Before becoming a finished product, RSHO™ goes through multiple quality tests by top cannabis industry and food laboratories.
For additional information on the new RSHO™ MCT oil products available for import, visit the HempMeds Brasil™ website here.
FACT: The National Institutes of Health has a patent on the therapeutic uses of CBD.
In 1998, a group of scientists on behalf of the National Institutes of Health filed a patent with the US Patent Office that stated that cannabinoids have medical value.
Co-authored by Nobel Laureate Julius Axelrod, Patent #6,630,507 was awarded to the National Institutes of Health in 2003, just five years after it was filed. This patent is titled, “Cannabinoids as antioxidants and neuroprotectants.”
FACT: The NIH acknowledges the therapeutic properties and potential uses of CBD.
Colloquially called “the ‘507 patent,” this document describes the potential therapeutic values of non-psychoactive cannabinoids. It describes cannabidiol (CBD) in particular as being a potent antioxidant – stronger than either vitamin C and vitamin E. CBD is also described as having neuroprotective properties, meaning the NIH believes it may protect the brain and nervous system from damage due to head trauma like concussions or brain damage from strokes.
The patent also describes CBD as being very non-toxic, with no possibility of fatal overdose and no damage demonstrated “large, acute doses” of 700mg CBD/day (which is hundreds of times more CBD than most people would ever ingest).
FACT: This patent flies in the face of the Schedule I status of cannabis, which defines cannabis as having “no medical value.”
The US government doesn’t officially recognize the medical potential of marijuana, at least in part because the studies about its potential therapeutic benefits have been small, and there have been no large-scale clinical trials on the plant. However, certain components of marijuana have been made into pharmaceutical drugs for decades like Marinol, which is a synthetic version of THC to treat chemotherapy symptoms.
FACT: The ‘507 patent also means anyone wanting to develop a pharmaceutical drug using CBD would have to receive a license from the NIH to do so.
Fortunately, we have that covered. Medical Marijuana Inc.’s joint venture with KannaLife Sciences includes exclusive and non-exclusive license agreements with the NIH to develop CBD into viable medicines. This is yet another way that we are working towards a future in which cannabinoids are viewed as the true therapeutic powerhouses emerging research indicates they are.
FACT: Contrary to popular belief, this patent isn’t for medical marijuana.
The ‘507 patent covers the potential medical use of non-psychotropic compounds in cannabis, particularly CBD. The ‘507 patent specifically avoids psychotropic cannabinoids (like THC).
FACT: The ‘507 Patent is among the strongest cases for our CBD business model.
Legitimacy is everything in this world. Operating with the knowledge that one of the most venerable institutions in the world has cataloged the many potential benefits of CBD motivates every business decision we make.
Washington, DC (November 19, 2015) – Today, Representative Earl Blumenauer (D-OR), joined by Representatives Dana Rohrabacher (R-CA), Steve Cohen (D-TN), Sam Farr (D-CA), Barbara Lee (D-CA), Ted Lieu (D-CA), and Jim McDermott (D-WA), sent a letter to President Obama calling for new leadership at the Drug Enforcement Administration (DEA) following recent comments by the Acting Administrator, referring to the notion of smoking medical marijuana as ‘a joke.’
“Mr. Rosenberg’s comments are outrageous and misleading. The last 20 years has shown overwhelming testimonial evidence of the benefits of medical marijuana, leading 23 states, DC, and Guam to change their laws,” said Representative Blumenauer. “President Obama has taken action to respect state medical marijuana laws. Mr. Rosenberg is out of step with the Administration and out of touch. It’s time for new leadership.”
In the letter, the lawmakers also call out Rosenberg’s hypocrisy in statements he made highlighting a lack of information demonstrating the safety or effectiveness of marijuana as medicine. Current federal policies make it very difficult for doctors and scientists to conduct the medical research with marijuana necessary to obtain this information, and the DEA has been integral to limiting access to marijuana that can be legally used for research.
“The real joke is that the DEA has played a huge role in propping up federal policies that have systematically blocked research of marijuana’s medicinal value. If there are any questions about its safety or effectiveness, it’s because the federal government continues to stymie science,” said Representative Blumenauer.
Yesterday, November 18, Representative Blumenauer took to the floor of the House calling for a new DEA chief. Additionally, a petition organized by Marijuana Majority on Change.org demanding that Rosenberg be fired has garnered more than 90,000 signatures.
Cannabidial - Stay Tuned 
You must be logged in to post a comment.